Sangamo Therapeutics is a clinical-stage genomic medicine company focused on treatments for serious neurological diseases. Sangamo's core technology uses engineered zinc finger proteins (ZFPs) configured as zinc finger repressors (ZFRs) that silence disease-causing genes through epigenetic modification — without cutting DNA — delivered to target cells via adeno-associated virus (AAV) vectors. Sangamo argues this approach offers durable, single-dose gene silencing with a potentially better safety profile than CRISPR-based editing. Sangamo has no approved products and generates revenue through licensing and collaboration agreements. Its lead wholly owned clinical programs include ST-503, a ZFR targeting the Nav1.7 pain signaling gene for neuropathic pain (Phase 1/2 enrolling, data expected Q4 2026); ST-506, a ZFR for prion disease targeting first-in-human dosing in mid-2026; and ST-920, a gene therapy for Fabry disease with a rolling BLA submission initiated in late 2025. Sangamo is seeking a commercial partner for ST-920 and a new partner for its hemophilia A program after Pfizer terminated that collaboration in 2025. A second key platform is the STAC-BBB capsid, a proprietary AAV engineered to cross the blood-brain barrier after IV administration, which Sangamo has licensed to Genentech, Astellas, and Lilly for CNS programs. Sangamo has received roughly $911M in upfront fees, milestones, and equity proceeds to date, with up to $4.8B in potential future milestones across active collaborations. Without a Fabry partnership or new capital, Sangamo has disclosed it faces going concern risk.